Candel Therapeutics Inc (CADL) Institutional Ownership Tracker (Q2 2026)

CADL ranks #3848 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

CADL is a top-conviction position for Acorn Capital Advisors, LLC — at 9.8% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in CADL belongs to FMR LLC, but the position matters far more to Acorn Capital Advisors, LLC, who has 9.8% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

GAMMA Investing LLC has added to its CADL position for two straight quarters, increasing it by $19.7K to reach $20.9K today.

CADL is down 8.1% today, but institutions show net buying of $104.1M this quarter — a divergence between today's price move and the underlying institutional flow.

CADL reported a net loss of $88.5M over the trailing twelve months.

• Not yet profitable — net loss of $88.5M over the trailing twelve months
• Revenue declined 0.0% year over year
• Net income declined year over year, from -$22.1M to -$88.5M
• Operating cash flow was negative, using $38.3M in cash
• Current ratio of 13.49x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.41x equity — within a conventional range